On Wall Street, it’s out with tech and mega-caps and in with small-caps, cyclicals and value. Investors have been rotating away from the big names that...
Once touted as promising treatments and by some even a cure, the World Health Organization dashes those claims, finding no benefit in the use of four popular Covid-19 treatments (remdesivir, hydroxychloroquine, lopinavir, or interferon-beta-1a)...
Bioprocessors have had a good handle on viral safety, but they need to keep their grip as they shift toward continuous processing and boost production of...
COVID Antibody Drugs From Regeneron, Eli Lilly Raise Concerns About Supply Shortages Tyler Durden Sat, 11/28/2020 - 17:30 Powerful drugs recently authorized by the FDA are...
The U.S. government will start distributing Regeneron Pharmaceuticals Inc.’s newly authorized Covid-19 antibody combination on Nov. 24, beginning with more than 30,000 treatment courses, a health...
The U.S. Food and Drug Administration issued emergency use authorization for Regeneron Pharmaceuticals Inc.’s Covid-19 antibody therapy, an experimental treatment given to U.S. President Donald Trump...
Regeneron announced that its REGN-COV2 investigational antibody cocktail therapy for the treatment of COVID-19, has been granted Emergency Use Authorization (EUA) by the US Food and...
AstraZeneca starts new Covid-19 prevention trials of antibody cocktail
UPDATED: Eli Lilly's Covid-19 partner AbCellera pays $90M for some very special mice as Peter Thiel jumps on the board and IPO rumors heat up
Eli Lilly's Covid-19 partner AbCellera pays $90M for some very special mice as IPO rumors heat up
Covid-19 roundup: EU begins reviewing Moderna vaccine; CureVac and EU agree to 405M-dose deal
Covid-19 roundup: CureVac and EU agree to 405M-dose deal; WHO warns that vaccine news is no panacea
What monoclonal antibodies are – and why we need them as well as a vaccine
How Effective Will Lilly’s Bamlanivimab be in the Battle Against Covid-19?
Treatments for people with early COVID-19 infection is an urgent research focus
Exclusive: WHO-led Covid drug scheme doubles down on antibodies, steroids and shuns remdesivir
U.S. allows emergency use of first Covid-19 antibody drug
TFF Teams Up With Augmenta For Covid-19 Antibody Therapies; Shares Pop 7%
Regeneron, Lilly Setbacks Raise Questions on the Effectiveness of Antibodies in Severe COVID-19
Regeneron Halts Covid-19 Trial For High-Flow Oxygen Patients; Shares Fall
NEJM: clinical trial indicates monoclonal antibody lowered hospitalizations and emergency visits
Yearlong study of coronavirus in frontline workers underway
Regeneron’s Covid-19 antibody treatment cut medical visits in trial
U.S. strikes deal with Lilly for potential Covid-19 antibody drug
SARS-CoV-2 Uses a Second Receptor, Neuropilin-1, to Infect Human Cells
Gilead’s COVID-19 drug Veklury falls short in WHO’s global trial
Regeneron Scores FDA Nod For Ebola Treatment
NIH study aims to identify promising COVID-19 treatments for larger clinical trials
3 COVID-19 Antibody Stocks That Are Leading the Race
What you – and doctors – should watch for if you have COVID-19